vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $9.6M, roughly 1.4× Red Cat Holdings, Inc.). Red Cat Holdings, Inc. runs the higher net margin — -166.0% vs -488.0%, a 321.9% gap on every dollar of revenue. On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs -22.4%). Red Cat Holdings, Inc. produced more free cash flow last quarter ($-24.5M vs $-57.1M).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

OCUL vs RCAT — Head-to-Head

Bigger by revenue
OCUL
OCUL
1.4× larger
OCUL
$13.3M
$9.6M
RCAT
Growing faster (revenue YoY)
RCAT
RCAT
+1010.7% gap
RCAT
988.2%
-22.4%
OCUL
Higher net margin
RCAT
RCAT
321.9% more per $
RCAT
-166.0%
-488.0%
OCUL
More free cash flow
RCAT
RCAT
$32.6M more FCF
RCAT
$-24.5M
$-57.1M
OCUL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
OCUL
OCUL
RCAT
RCAT
Revenue
$13.3M
$9.6M
Net Profit
$-64.7M
$-16.0M
Gross Margin
88.0%
6.6%
Operating Margin
-526.5%
-181.7%
Net Margin
-488.0%
-166.0%
Revenue YoY
-22.4%
988.2%
Net Profit YoY
-33.6%
-29.0%
EPS (diluted)
$-0.27
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
RCAT
RCAT
Q4 25
$13.3M
Q3 25
$14.5M
$9.6M
Q2 25
$13.5M
Q1 25
$10.7M
$1.6M
Q4 24
$17.1M
$0
Q3 24
$15.4M
Q2 24
$16.4M
Q1 24
$14.8M
$5.8M
Net Profit
OCUL
OCUL
RCAT
RCAT
Q4 25
$-64.7M
Q3 25
$-69.4M
$-16.0M
Q2 25
$-67.8M
Q1 25
$-64.1M
$-23.1M
Q4 24
$-48.4M
$-13.3M
Q3 24
$-36.5M
Q2 24
$-43.8M
Q1 24
$-64.8M
$-5.5M
Gross Margin
OCUL
OCUL
RCAT
RCAT
Q4 25
88.0%
Q3 25
87.8%
6.6%
Q2 25
85.6%
Q1 25
88.2%
-52.2%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
90.8%
Q1 24
91.0%
18.8%
Operating Margin
OCUL
OCUL
RCAT
RCAT
Q4 25
-526.5%
Q3 25
-472.3%
-181.7%
Q2 25
-502.6%
Q1 25
-597.5%
-765.7%
Q4 24
-296.1%
Q3 24
-298.2%
Q2 24
-265.1%
Q1 24
-214.0%
-76.0%
Net Margin
OCUL
OCUL
RCAT
RCAT
Q4 25
-488.0%
Q3 25
-477.3%
-166.0%
Q2 25
-503.9%
Q1 25
-598.7%
-1418.9%
Q4 24
-283.3%
Q3 24
-236.6%
Q2 24
-266.3%
Q1 24
-438.9%
-93.9%
EPS (diluted)
OCUL
OCUL
RCAT
RCAT
Q4 25
$-0.27
Q3 25
$-0.38
$-0.16
Q2 25
$-0.39
Q1 25
$-0.38
$-0.27
Q4 24
$-0.25
Q3 24
$-0.22
Q2 24
$-0.26
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$737.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$654.3M
$253.3M
Total Assets
$808.1M
$286.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
RCAT
RCAT
Q4 25
$737.1M
Q3 25
$344.8M
Q2 25
$391.1M
Q1 25
$349.7M
Q4 24
$392.1M
Q3 24
$427.2M
Q2 24
$459.7M
Q1 24
$482.9M
Stockholders' Equity
OCUL
OCUL
RCAT
RCAT
Q4 25
$654.3M
Q3 25
$258.2M
$253.3M
Q2 25
$305.9M
Q1 25
$265.9M
$28.9M
Q4 24
$315.3M
$27.0M
Q3 24
$352.0M
Q2 24
$377.7M
Q1 24
$408.0M
$49.6M
Total Assets
OCUL
OCUL
RCAT
RCAT
Q4 25
$808.1M
Q3 25
$410.9M
$286.0M
Q2 25
$451.3M
Q1 25
$405.9M
$59.7M
Q4 24
$457.9M
$51.1M
Q3 24
$490.4M
Q2 24
$517.1M
Q1 24
$538.9M
$55.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
RCAT
RCAT
Operating Cash FlowLast quarter
$-54.2M
$-23.9M
Free Cash FlowOCF − Capex
$-57.1M
$-24.5M
FCF MarginFCF / Revenue
-430.9%
-254.2%
Capex IntensityCapex / Revenue
21.4%
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-216.9M
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
RCAT
RCAT
Q4 25
$-54.2M
Q3 25
$-50.7M
$-23.9M
Q2 25
$-55.2M
Q1 25
$-44.7M
$-15.9M
Q4 24
$-39.4M
$-10.1M
Q3 24
$-36.6M
Q2 24
$-24.8M
Q1 24
$-33.9M
$-4.1M
Free Cash Flow
OCUL
OCUL
RCAT
RCAT
Q4 25
$-57.1M
Q3 25
$-56.7M
$-24.5M
Q2 25
$-56.5M
Q1 25
$-46.6M
$-16.2M
Q4 24
$-39.6M
$-10.2M
Q3 24
$-36.6M
Q2 24
$-25.5M
Q1 24
$-34.1M
$-4.2M
FCF Margin
OCUL
OCUL
RCAT
RCAT
Q4 25
-430.9%
Q3 25
-390.0%
-254.2%
Q2 25
-419.7%
Q1 25
-435.6%
-992.9%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
-155.4%
Q1 24
-231.1%
-71.1%
Capex Intensity
OCUL
OCUL
RCAT
RCAT
Q4 25
21.4%
Q3 25
41.2%
6.9%
Q2 25
9.3%
Q1 25
18.1%
16.8%
Q4 24
1.2%
Q3 24
0.6%
Q2 24
4.5%
Q1 24
1.7%
0.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OCUL
OCUL

Segment breakdown not available.

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons